EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101

Yosuke Kawashima iD, Osamu Ishimoto, Eisaku Miyauchi iD, Tomohiro Sakakibara, Toshiyuki Harada, Kazuhiro Usui, Akira Inoue, Shunichi Sugawara

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.15076 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Yosuke Kawashima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This phase II trial was designed to evaluate the efficacy and safety of S‐1 combined with weekly irinotecan as a second‐ or third‐line treatment for patients with advanced or recurrent squamous cell lung cancer.

Methods

Patients with a body surface area 1.50 m 2 received oral S‐1 on days 1–14 at 80, 100, and 120 mg/day, respectively, and irinotecan on days 1 and 8 at 70 mg/m 2 every 3 weeks. The primary endpoint was the overall response rate, and the secondary endpoints were progression‐free survival, overall survival, and the incidence and severity of adverse effects.

Results

Between September 2011 and December 2014, 30 patients were enrolled in this study. The overall response rate was 6.7% (95% confidence interval [CI]: 0.8%–22.1%), and the disease control rate was 73.3%. The median progression‐free survival was 3.0 months (95% CI: 2.5–3.4 months), and the median overall survival was 10.5 months (95% CI: 5.6–13.7 months). Grade 3/4 treatment‐related adverse events were reported in ≥10% of the patients, including leukopenia (21%), neutropenia (21%), anemia (17%), anorexia (10%), and hypokalemia (10%).

Conclusions

Although the treatment‐related adverse events were manageable, the combination of weekly irinotecan and S‐1 did not have the expected effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsEpithelial CellsIrinotecanJapanNeoplasm Recurrence, Local

Stichwörter der Autor:innen

carcinomaclinical trialirinotecannon-small cell lungphase II

Substanzen

Irinotecan

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
  • Okino Medical Clinic, Sendai, Japan.
  • Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Respiratory Medicine, Tohoku Rosai Hospital, Sendai, Japan.
  • Department of Respiratory Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.
  • Division of Respirology, NTT Medical Center Tokyo, Tokyo, Japan.

ORCID-Profile: Yosuke Kawashima, Eisaku Miyauchi

Zitieren

APA

Kawashima, Y., Ishimoto, O., Miyauchi, E., Sakakibara, T., Harada, T., Usui, K., Inoue, A., & Sugawara, S. (2023). Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15076

Vancouver

Kawashima Y, Ishimoto O, Miyauchi E, Sakakibara T, Harada T, Usui K, et al. Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15076

BibTeX
@article{Kawashima2023,
  author = {Kawashima, Yosuke and Ishimoto, Osamu and Miyauchi, Eisaku and Sakakibara, Tomohiro and Harada, Toshiyuki and Usui, Kazuhiro and Inoue, Akira and Sugawara, Shunichi},
  title = {Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.15076}
}
Kostenlos starten →